Milan - Delayed Quote EUR
Regeneron Pharmaceuticals, Inc. (1REGN.MI)
510.80
-24.40
(-4.56%)
At close: May 5 at 11:25:09 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
14,085,700
14,202,000
13,117,200
12,172,900
16,071,700
Cost of Revenue
2,001,000
1,970,500
1,815,800
1,560,400
2,437,500
Gross Profit
12,084,700
12,231,500
11,301,400
10,612,500
13,634,200
Operating Expense
8,253,700
8,240,800
7,254,300
5,873,600
4,687,400
Operating Income
3,831,000
3,990,700
4,047,100
4,738,900
8,946,800
Net Non Operating Interest Income Expense
675,600
656,200
422,900
100,700
-11,500
Other Income Expense
477,600
133,000
-270,700
19,200
390,500
Pretax Income
4,984,200
4,779,900
4,199,300
4,858,800
9,325,800
Tax Provision
484,900
367,300
245,700
520,400
1,250,500
Net Income Common Stockholders
4,499,300
4,412,600
3,953,600
4,338,400
8,075,300
Diluted NI Available to Com Stockholders
4,499,300
4,412,600
3,953,600
4,338,400
8,075,300
Basic EPS
41.78
40.90
37.05
40.51
76.40
Diluted EPS
39.34
38.34
34.77
38.22
71.97
Basic Average Shares
107,625
107,900
106,700
107,100
105,700
Diluted Average Shares
114,125
115,100
113,700
113,500
112,200
Total Operating Income as Reported
3,831,000
3,990,700
4,047,100
4,738,900
8,946,800
Total Expenses
10,254,700
10,211,300
9,070,100
7,434,000
7,124,900
Net Income from Continuing & Discontinued Operation
4,499,300
4,412,600
3,953,600
4,338,400
8,075,300
Normalized Income
4,090,280.93
4,304,424.40
4,189,508.70
4,329,112.80
7,740,591
Interest Income
723,400
711,400
495,900
160,100
45,800
Interest Expense
47,800
55,200
73,000
59,400
57,300
Net Interest Income
675,600
656,200
422,900
100,700
-11,500
EBIT
5,032,000
4,835,100
4,272,300
4,918,200
9,383,100
EBITDA
5,527,700
5,318,000
4,693,300
5,259,600
9,669,300
Reconciled Cost of Revenue
2,001,000
1,970,500
1,815,800
1,560,400
2,437,500
Reconciled Depreciation
495,700
482,900
421,000
341,400
286,200
Net Income from Continuing Operation Net Minority Interest
4,499,300
4,412,600
3,953,600
4,338,400
8,075,300
Total Unusual Items Excluding Goodwill
453,100
117,200
-250,700
10,400
386,500
Total Unusual Items
453,100
117,200
-250,700
10,400
386,500
Normalized EBITDA
5,074,600
5,200,800
4,944,000
5,249,200
9,282,800
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
44,080.93
9,024.40
-14,791.30
1,112.80
51,791
12/31/2021 - 11/27/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade